Joanna Schaffer
Family · Houston, TXNPI 1528621760
Payments from drug & device makers
Across 205 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$787
- Lilly USA, LLC$528
- GSK$434
- Mylan Specialty L.p.$348
- Bayer$249
- Amgen$202
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,753100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 50 | $787 |
| Lilly USA, LLC | 28 | $528 |
| GSK | 22 | $434 |
| Mylan Specialty L.p. | 16 | $348 |
| Bayer | 16 | $249 |
| Amgen | 12 | $202 |
| Dexcom, Inc. | 9 | $165 |
| AstraZeneca | 8 | $145 |
| Pfizer | 5 | $101 |
| Inspire Medical Systems, Inc. | 4 | $91 |
| Corcept Therapeutics | 4 | $86 |
| Sanofi-aventis U.S. LLC | 4 | $83 |
| AbbVie | 3 | $69 |
| Exact Sciences | 3 | $56 |
| Abbott | 3 | $55 |
| Tandem Diabetes Care, Inc. | 2 | $43 |
| Sanofi | 2 | $40 |
| Johnson & Johnson | 3 | $40 |
| Boehringer Ingelheim | 2 | $38 |
| Merck | 1 | $34 |
| BETA Bionics, Inc. | 2 | $32 |
| Medtronic | 1 | $29 |
| Astellas Pharma US Inc | 2 | $28 |
| Edwards Lifesciences | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $20 |
How this compares
$3,753 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 150 | $239,738 |
| JardianceEmpagliflozin | 92 | $133,560 |
| MounjaroTirzepatide | 59 | $82,317 |
| RybelsusSemaglutide | 19 | $41,612 |
| TrulicityDulaglutide | 19 | $34,952 |
| FarxigaDapagliflozin Propanediol | 37 | $33,440 |
| KerendiaFinerenone | 24 | $32,624 |
| JanuviaSitagliptin Phosphate | 25 | $31,110 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $26,701 |
| Xigduo XrDapaglifloz Propaned/Metformin | 23 | $26,114 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $24,597 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $21,836 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $21,742 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $20,570 |
| TradjentaLinagliptin | 22 | $14,629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $787 | $281,350169 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Synjardy Xr | $38 | $178,487139 claims |
| Lilly USA, LLCMounjaro, Trulicity | $528 | $117,27078 claims |
| AstraZenecaFarxiga | $145 | $33,44037 claims |
| BayerKerendia | $249 | $32,62424 claims |
| MerckJanuvia | $34 | $31,11025 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $83 | $21,74216 claims |
| AbbVieSynthroid | $69 | $88820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Houston
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- David WeirDallas$959K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.